Medidata, a global provider of cloud-based solutions for clinical research in life sciences, has expanded its partnership with Peking University Clinical Research Institute (PUCRI), an academic center dedicated to enhancing the development of high-quality clinical research and health innovation in China. Leveraging the research institute’s extensive clinical development network, experience and resources, the partnership will accelerate the adoption of the Medidata Clinical Cloud platform across China and, in doing so, optimize local drug development programs by bringing operational efficiencies and greater speed to clinical trials.

Weigang Fang, vice president of Peking University Health Science Center and director of PUCRI, said, “In China, paper-based clinical trials are still mainstream, especially at Chinese domestic companies. By working with Medidata, we look forward to further advancing clinical development in the country, serving as a bridge between globally-leading technology and innovative drug development.”

Professor Yangfeng Wu, executive associate director of PUCRI, said, “The enhanced partnership between PUCRI and Medidata will provide better services and inject new vitality in drug development in China.”

Combining cloud-based solutions with experience in clinical development, Medidata and PUCRI have collaborated for several years to introduce innovative technology into clinical research in China. Together, they are helping life sciences companies improve operational efficiencies and increase productivity across China’s clinical research programs. Medidata and PUCRI will provide life sciences companies in China with increased accessibility to technology that streamlines clinical trials and, ultimately, helps to accelerate the delivery of novel therapies to patients.